A Study Of Plasma Homocysteine And Serum Ferritin Level Alternation Between Pre-chemotherapy And Post-chemotherapy AML-M2a Patients

ObjectiveThrough testing the plasma Homocysteine (p-Hcy), serum iron protein (SF) inpatients with acute myelogenous leukemia (AML) M2a type patients before and afterchemotherapy level changes, and analyzes of the relationship between p-Hcy, SF andthe white blood cell count, thus further study AML-M2a type in patients with thechange of the amino acid metabolism level; And understand the relationship betweentumor load,p-Hcy and SF in AML-M2a type patients.Method：A total of30cases of AML-M2a group, in March2010to October2011were the firsthospital of Zhengzhou University in newly diagnosed adult male AML-M2a patientschemotherapy. The AML-M2a remission group in16cases, AML-M2a group patientswith standard chemotherapy of DA regimen1-2after treatment achieved completeremission; AML-M2a without remission group14cases, for the AML-M2a grouppatients with standard chemotherapy of DA regimen after2weeks of treatment ofpartial remission and non remission. A control group of20cases for the same period,the first hospital of Zhengzhou University examination of normal adult male. Theabove groups to visit check routine. Application of circulating enzymatic method forthe detection of group AML-M2a before chemotherapy, after standard chemotherapyof DA regimen (1-2regimen)2weeks after p-Hcy level; chemiluminescence detectionbefore chemotherapy, after standard chemotherapy of DA regimen (1-2regimen)2weeks after SF level. The control group in the p-Hcy, SF level examination. Statisticalmethods: using SPSS16.0statistical software for data analysis. Measurement datausing the mean±SD （x±s） said. Comparison of general data, compared with thecontrol group with single factor analysis of variance; before chemotherapy, after compared using a paired t test; index correlation analysis with linear correlationanalysis. Inspection standard forα=0.05Result:1.AML-M2a remission group, AML-M2a without remission patients beforechemotherapy p-Hcy [(13.70+4.51) mol/L,(18.23+7.81) mol/L], SF [(473.35+96.07) ng/ml,(510.76+108.91) ng/ml than that of the control group (9.49[]+3.49) mol/L,(55.55+30.96) ng/ml were increased (P <0.001, P <0.001).2. AML-M2a remission after chemotherapy in patients with p-Hcy (10.44+3.44) mol/L, SF (332.79+76.08) ng/ml water than the average before chemotherapy [(13.70+4.51) mol/L,(473.35+96.07) ng/ml] were significantly reduced (P <0.001, P <0.001), but the serum ferritin level is still higher than the control group (P <0.001).3. AML-M2a without remission after chemotherapy in patients with p-Hcy (15.07+5)mol/L, SF (448.50+105.18) ng/ml water than the average before chemotherapy[(18.23+7.81) mol/L,(510.76+108.91) ng/ml] no significant difference (P=0.055, P=0.149).4. AML-M2a patients before chemotherapy p-Hcy and SF levels there are linearcorrelation between, were positively correlated (r=0.522, P=0.003, n=30);AML-M2a patients before chemotherapy p-Hcy levels and WBC there are linearcorrelation between, were positively correlated (r=0.515, P=0.004, n=30);AML-M2a patients before chemotherapy SF levels and WBC there are linearcorrelation between, were positively correlated (r=0.504, P=0.005, n=30).Conclusion:AML-M2a patients p-Hcy, SF metabolism abnormality. AML-M2a patientswith p-Hcy, SF level changes may be related to the patient in vivo tumor load on.